etoposide/viduriavimas

Nuoroda įrašoma į mainų sritį

Pasirinkite rūšiavimo tipą

15 rezultatus

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Lung cancer is the most common cancer, accounting for 20% of cancer-related deaths worldwide. In 2015, an estimated 610,200 patients (22 per cent of cancer-related deaths) died of lung cancer. Non-small cell lung cancer ((NSCLC)) accounts for 80% to 85% of lung cancer. Most patients are locally

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

PRIMARY OBJECTIVES: I. To evaluate the safety and feasibility of human lysozyme goat milk (hLZ) treatment by assessing: Ia: Type, frequency, severity, attribution, time course and duration of adverse events, including diarrhea, bloodstream/intestinal infections. Ib. Patients' ability to drink the

FOLFIRINOX for 2nd-line Treatment of BTC

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Biliary tract cancer (BTC) is a common term for malignant tumors that occur in gallbladder and bile duct, the path in which bile is released. According to the anatomical location, biliary tract cancer is divided into intrahepatic cholangiocarcinoma and extrahepatic

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells in a background of inflammatory cells. The majority of patients with HL have a good outcome with first-line chemotherapy such as ABVD (doxorubicin, bleomycin, vinblastine and

Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

PRIMARY OBJECTIVES: I. To evaluate the safety and feasibility of human lysozyme goat milk (hLZ) treatment by assessing type, frequency, severity, attribution, time course and duration of adverse events, including diarrhea, bloodstream/intestinal infections. II. To evaluate the safety and feasibility

Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Biliary tract carcinomas (BTCs) are invasive adenocarcinomas that arise from the epithelial cells of the biliary tree, which comprises intrahepatic and extrahepatic bile ducts, and the gallbladder. Even though BTCs are considered as rare tumors, they represent about 30% of the total primary liver

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Patients who meet the eligibility criteria and are randomized to one of the treatment arms, will receive either topotecan alone intravenously at 1.25 mg/m2 on days 1 to 5 of a 21-day cycle or pembrolizumab alone administered intravenously at 200mg every 21 days. During the study period, patients

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Lung cancer is the leading cause of cancer-related mortality worldwide. A report published by the WHO in February 2014, estimated there were 1.83 million new cases and 1.59 million deaths worldwide in 2012. The American Lung Association reports 399,431 Americans living with lung cancer, with an

Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

In the United States, the incidence of acute myeloid leukemia (AML) is approximately 3.5 cases per 100,000 persons per year. Approximately 13,000 people were diagnosed with AML in 2009 and 9,000 died of the disease, making AML the 6th leading cause of cancer death. Over the past three decades, AML

Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

1. INDUCTION CHEMOTHERAPY - For patients randomized to receive Idarubicin (Arm I, AI regimen) will be given Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) along with Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3). - For patients randomized to receive

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

This is open-label, single center, 2-cohort phase I dose-escalation study of vandetanib administered orally on continuous daily dosing schedule + oral etoposide among adult patients with recurrent or relapsing malignant glioma. Patients will be stratified based on whether they are receiving EIAEDs &

A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

* TREATMENT PLANS FOR FIRST-LINE AND SECOND LINE CHEMOTHERAPY 1. First-line Chemotherapy 1.1 PACE and ACE Treatment Scheme of PACE and ACE* Cyclophosphamide 650 mg/m2, i.v. Day 1 Epirubicin 60 mg/m2, i.v. Day 1 Etoposide 55 mg/m2/d, i.v. Day 1-3 Prednisolone 60 mg/m2/d, p.o. Day 1-7 - For ACE,

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVES: I. Determine the efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing severe oral mucositis induced by total body irradiation and high dose chemotherapy in patients with hematologic malignancies. II. Compare the incidence of severe oral mucositis, the use of

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVES: I. Determine the efficacy of recombinant keratinocyte growth factor in reducing the duration of severe oral mucositis induced by total body irradiation and high dose chemotherapy in patients with hematologic malignancies. II. Determine the incidence and duration of severe oral mucositis,

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais